Ljubljana, 30 August (STA) - The group around the Ljubljana-based pharmaceutical wholesaler Salus generated EUR 321 million in net sales revenue in the first six months of the year, which is 11% more year-on-year. Its net profit increased year-on-year by around a third to EUR 6.8 million, the group said in the report published on Friday.
The group's profit from regular operations and profit from regular operations before amortisation both increased by around a third to EUR 8.8 million and just under EUR 12.7 million, respectively.
The group performed above plan in the first six months, Salus said. In the absence of unexpected or extraordinary events it expects to exceed the plans also at the annual level, which would have the group generate EUR 672 million in net sales revenue with a net profit of EUR 9 million.
In January 2023, Salus signed a contract with several municipalities in the northeast to purchase Maribor's pharmaceuticals wholesaler Farmadent. According to the newest report, the conditions were not met by January this year and so the contract was terminated. Salus added that it remains interested in Farmadent.
Last year Salus completed the purchase of a 49% stake in Medorion, a Croatian company involved in the treatment of rare diseases. In March 2024 the companies signed an addendum providing for an adjusted buyer's payment of EUR 564,772, with the possibility of further payments up to a maximum total of EUR 900,000 if the remaining conditions were met.
